Kestra Advisory Services LLC Lowers Position in Boston Scientific Corporation $BSX

Key Points

• Kestra Advisory Services LLC reduced its stake in Boston Scientific Corporation by 13.6%, bringing its ownership to 187,230 shares worth approximately $18.9 million after selling 29,366 shares in the first quarter.
• Other institutional investors, including GAMMA Investing LLC and Northern Trust Corp, increased their positions in Boston Scientific, with GAMMA boosting its stake by an impressive 11,720.3%.
• Boston Scientific recently reported earnings that exceeded analyst expectations, with $5.06 billion in revenue and an EPS of $0.75, while setting guidance for Q3 2025 at 0.700-0.720 EPS.

Kestra Advisory Services LLC lowered its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 13.6% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 187,230 shares of the medical equipment provider's stock after selling 29,366 shares during the period. Kestra Advisory Services LLC's holdings in Boston Scientific were worth $18,888,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Boston Scientific by 1.3% in the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock worth $13,577,311,000 after acquiring an additional 1,697,945 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in shares of Boston Scientific by 2.5% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 22,312,967 shares of the medical equipment provider's stock valued at $1,992,994,000 after purchasing an additional 554,388 shares during the last quarter. Invesco Ltd. increased its position in Boston Scientific by 5.3% during the 1st quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider's stock worth $1,677,124,000 after purchasing an additional 834,274 shares in the last quarter. Northern Trust Corp lifted its stake in Boston Scientific by 18.0% in the 4th quarter. Northern Trust Corp now owns 14,595,627 shares of the medical equipment provider's stock valued at $1,303,681,000 after purchasing an additional 2,221,790 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in Boston Scientific by 10.8% in the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider's stock valued at $1,426,779,000 after buying an additional 1,383,524 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Trading Down 0.4%

Shares of Boston Scientific stock traded down $0.45 on Wednesday, reaching $105.94. 5,687,498 shares of the company's stock were exchanged, compared to its average volume of 7,524,457. The firm's 50-day moving average is $104.27 and its two-hundred day moving average is $102.15. The company has a market capitalization of $156.98 billion, a P/E ratio of 63.06, a price-to-earnings-growth ratio of 2.53 and a beta of 0.66. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a 52 week low of $79.03 and a 52 week high of $108.94.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's revenue was up 22.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Leerink Partners began coverage on Boston Scientific in a research report on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective on the stock. Erste Group Bank upgraded Boston Scientific to a "strong-buy" rating in a report on Thursday, May 8th. Barclays raised their price objective on shares of Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a report on Thursday, July 24th. Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Finally, Robert W. Baird raised their target price on Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Boston Scientific presently has an average rating of "Buy" and a consensus target price of $117.50.

Insiders Place Their Bets

In related news, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the sale, the executive vice president owned 23,600 shares of the company's stock, valued at $2,469,268. This trade represents a 42.32% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 345,029 shares of company stock valued at $35,976,603. 0.50% of the stock is currently owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.